Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Twist Bioscience Corp (NQ: TWST )

46.44 -1.55 (-3.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Twist Bioscience Corp

< Previous 1 2 3 4 5 6 7 8 Next >
Twist Bioscience Reports First Quarter 2022 Financial Results
From Twist Bioscience Corporation
Via Business Wire
Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Releases Inaugural ESG Report Highlighting Achievements and Initiatives in Diversity and Sustainability
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2022 First Quarter Financial Results on Friday, February 4, 2022
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience’s Comprehensive DNA Synthesis Capabilities Expanded as Industry-Leading Enzymatic Synthesis Process Unveiled at Annual J.P. Morgan Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Creates Custom Whole Exome Target Enrichment Panel for Canine Genomic Research
From Twist Bioscience Corporation
Via Business Wire
Revelar Biotherapeutics and Twist Bioscience Announce RBT-0813 Neutralizes SARS-CoV-2 Omicron (B.1.1.529/BA.1) and Delta (B.1.617.2) Variants
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches 96-Plex Library Prep Kit for Low Pass High Throughput Next-Generation Sequencing
From Twist Bioscience Corporation
Via Business Wire
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies Against GPCR Targets
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches Circulating Tumor DNA Reference Controls for Development of Liquid Biopsy Assays
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Announces Participation in SRC-SIA Webinar on the Decadal Plan for Semiconductors
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at Upcoming Virtual Conferences
From Twist Bioscience
Via Business Wire
Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Expands Partnership with Invetx to Include Discovery of Best-in-Class Antibodies to Treat Multiple Diseases in Cats and Dogs
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Named in Inc.’s First Annual Best-Led Companies List
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2021 Fourth Quarter and Full Year Financial Results on Monday, November 22, 2021
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches Exome 2.0 for Genomics Research
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Appoints Steffen Hellmold as Senior Vice President, Business Development, Data Storage
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience and CENTOGENE to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Expands Expert Custom Alliance Panel Offering
From Twist Bioscience Corporation
Via Business Wire
Illumina Ventures Closes $325 Million Fund Supporting Start-ups in Healthcare Innovation
SOURCE: Illumina 
Via 3BL Media
Twist Bioscience Appoints Dennis Cho as Senior Vice President, General Counsel and Chief Ethics and Compliance Officer
From Twist Bioscience
Via Business Wire
Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SARS-CoV-2, Including Alpha, Beta, and Gamma Strains, in Preclinical Studies
From Twist Bioscience Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.